{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:41:13Z","timestamp":1761237673971},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2009,11,29]],"date-time":"2009-11-29T00:00:00Z","timestamp":1259452800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Science Inc"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1007\/s11906-009-0077-7","type":"journal-article","created":{"date-parts":[[2009,11,28]],"date-time":"2009-11-28T01:04:06Z","timestamp":1259370246000},"page":"456-462","source":"Crossref","is-referenced-by-count":9,"title":["Direct renin inhibition: An update"],"prefix":"10.1007","volume":"11","author":[{"given":"Rekha","family":"Pinto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan H.","family":"Gradman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,11,29]]},"reference":[{"issue":"SupplA","key":"77_CR1","first-page":"A157","volume":"9","author":"B. Dahl\u00f6f","year":"2007","unstructured":"Dahl\u00f6f B, Anderson DR, Arora V, et al.: Aliskiren, a direct renin inhibitor, provides antihypertensive efficacy and excellent tolerability independent of age or gender in patients with hypertension [abstract]. J Clin Hypertens 2007, 9(Suppl A):A157.","journal-title":"J Clin Hypertens"},{"key":"77_CR2","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0140-6736(07)61124-6","volume":"370","author":"S. Oparil","year":"2007","unstructured":"Oparil S, Yarows SA, Patel S, et al.: Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007, 370:221\u2013229.","journal-title":"Lancet"},{"key":"77_CR3","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1016\/j.amjhyper.2004.03.279","volume":"17","author":"A.H. Gradman","year":"2004","unstructured":"Gradman AH, Schmieder RE, Lins RL, et al.: Aliskiren, a novel orally effective renin inhibitor, provides antihypertensive efficacy and placebo-like tolerability similar to an AT1-receptor blocker in hypertensive patients [abstract]. Am J Hypertens 2004, 17:S108.","journal-title":"Am J Hypertens"},{"key":"77_CR4","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1161\/01.HYP.0000101688.17370.87","volume":"42","author":"A. Stanton","year":"2003","unstructured":"Stanton A, Jensen C, Nussberger J, O\u2019Brien E: Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003, 42:1137\u20131143.","journal-title":"Hypertension"},{"key":"77_CR5","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1161\/CIRCULATIONAHA.107.750745","volume":"119","author":"R.E. Schmieder","year":"2009","unstructured":"Schmieder RE, Philipp T, Guerediaga J, et al.: Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. Circulation 2009, 119:417\u2013425.","journal-title":"Circulation"},{"key":"77_CR6","unstructured":"European Medicines Agency: European Medicines Agency recommends new contraindication and warning for Rasilez and other aliskiren medicines [press release]. London: February 19, 2009. Available at http:\/\/www.emea.europa.eu\/pdfs\/human\/press\/pr\/8952309en.pdf . Accessed September 17, 2009."},{"issue":"suppl27","key":"77_CR7","first-page":"790","volume":"119","author":"J. Pool","year":"2006","unstructured":"Pool J, Gradman A, Kolloch R, et al.: Aliskiren, a novel renin inhibitor, provides long-term suppression of the renin system, when used alone or in combination with hydrochlorothiazide in the treatment of hypertension. Eur Heart J 2006, 119(suppl 27):790.","journal-title":"Eur Heart J"},{"key":"77_CR8","doi-asserted-by":"crossref","unstructured":"Palatini P, Jung W, Shlyakhto E, et al.: Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study. J Hum Hypertens 2009 May 21 (Epub ahead of print).","DOI":"10.1038\/jhh.2009.38"},{"key":"77_CR9","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.jacc.2006.11.032","volume":"49","author":"B.H. Oh","year":"2007","unstructured":"Oh BH, Mitchell J, Herron JR, et al.: Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 2007, 49:1157\u20131163.","journal-title":"J Am Coll Cardiol"},{"key":"77_CR10","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/HJH.0b013e3280103a6b","volume":"25","author":"A. Villamil","year":"2007","unstructured":"Villamil A, Chrysant SG, Calhoun D, et al.: Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007, 25:217\u2013226.","journal-title":"J Hypertens"},{"key":"77_CR11","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3317\/jraas.2007.028","volume":"8","author":"Y. Uresin","year":"2007","unstructured":"Uresin Y, Taylor A, Kilo C, et al.: Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst 2007, 8:190\u2013198.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"77_CR12","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/1470320308096411","volume":"9","author":"R. Dietz","year":"2008","unstructured":"Dietz R, Dechend R, Yu CM, et al.: Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension. J Renin Angiotensin Aldosterone Syst 2008, 9:163\u2013175.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"77_CR13","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.amjhyper.2007.04.001","volume":"20","author":"J.E. Sealey","year":"2007","unstructured":"Sealey JE, Laragh JH: Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness. Am J Hypertens 2007, 20:587\u2013597.","journal-title":"Am J Hypertens"},{"key":"77_CR14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1161\/HYPERTENSIONAHA.107.101287","volume":"51","author":"D.J. Campbell","year":"2008","unstructured":"Campbell DJ: Interpretation of plasma renin concentration in patients receiving aliskiren therapy. Hypertension 2008, 51:15\u201318.","journal-title":"Hypertension"},{"key":"77_CR15","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1161\/HYPERTENSIONAHA.108.109967","volume":"51","author":"A.H. Danser","year":"2008","unstructured":"Danser AH, Charney A, Feldman DL, et al.: The renin rise with aliskiren: it\u2019s simply stoichiometry. Hypertension 2008, 51:e27\u2013e28.","journal-title":"Hypertension"},{"key":"77_CR16","first-page":"A39","volume":"11s1","author":"A. Stanton","year":"2009","unstructured":"Stanton A, Gradman AH, Schmieder R, et al.: Aliskiren does not cause paradoxical rises in blood pressure [abstract P-56]. J Clin Hypertens 2009, 11(s1):A39.","journal-title":"J Clin Hypertens"},{"key":"77_CR17","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1007\/s00125-007-0795-9","volume":"50","author":"D.J. Kelly","year":"2007","unstructured":"Kelly DJ, Zhang Y, Moe G, et al.: Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia 2007, 50:2398\u20132404.","journal-title":"Diabetologia"},{"key":"77_CR18","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1161\/HYPERTENSIONAHA.107.108845","volume":"52","author":"D.L. Feldman","year":"2008","unstructured":"Feldman DL, Jin L, Xuan H, et al.: Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 2008, 52:130\u2013136.","journal-title":"Hypertension"},{"key":"77_CR19","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1161\/CIRCULATIONAHA.108.767202","volume":"117","author":"N.D. Fisher","year":"2008","unstructured":"Fisher ND, Jan Danser AH, Nussberger J, et al.: Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation 2008, 117:3199\u20133205.","journal-title":"Circulation"},{"key":"77_CR20","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1172\/JCI0214276","volume":"109","author":"G. Nguyen","year":"2002","unstructured":"Nguyen G, Delarue F, Burckle C, et al.: Pivotal role of the renin\/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002, 109:1417\u20131427.","journal-title":"J Clin Invest"},{"key":"77_CR21","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1111\/j.1523-1755.2004.00653.x","volume":"65","author":"D. Zeeuw de","year":"2004","unstructured":"de Zeeuw D, Remuzzi G, Parving HH, et al.: Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004, 65:2309\u20132320.","journal-title":"Kidney Int"},{"key":"77_CR22","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","volume":"358","author":"H.H. Parving","year":"2008","unstructured":"Parving HH, Persson F, Lewis JB, et al.; AVOID Study Investigators: Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008, 358:2433\u20132446.","journal-title":"N Engl J Med"},{"key":"77_CR23","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1161\/CIRCULATIONAHA.108.826214","volume":"119","author":"S.D. Solomon","year":"2009","unstructured":"Solomon SD, Appelbaum E, Manning WJ, et al.; Aliskiren in Left Ventricular Hypertrophy (ALLAY) Trial Investigators: Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009, 119:530\u2013537.","journal-title":"Circulation"},{"key":"77_CR24","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1161\/HYPERTENSIONAHA.108.116350","volume":"52","author":"D. Westermann","year":"2008","unstructured":"Westermann D, Riad A, Lettau O, et al.: Renin inhibition improves cardiac function and remodeling after myocardial infarction independent of blood pressure. Hypertension 2008, 52:1068\u20131075.","journal-title":"Hypertension"},{"key":"77_CR25","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ehj.2003.10.030","volume":"25","author":"R. Latini","year":"2004","unstructured":"Latini R, Masson S, Anand I, et al., for the Val-HeFT Investigators: The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J 2004, 25:292\u2013299.","journal-title":"Eur Heart J"},{"key":"77_CR26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/CIRCHEARTFAILURE.107.740704","volume":"1","author":"J.J.V. McMurray","year":"2008","unstructured":"McMurray JJV, Pitt B, Latini R, et al., for the Aliskiren Observation of Heart Failure Treatment (ALOFT) Investigators: Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008, 1:17\u201324.","journal-title":"Circ Heart Fail"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-009-0077-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-009-0077-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-009-0077-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T20:14:24Z","timestamp":1559420064000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-009-0077-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,29]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["77"],"URL":"https:\/\/doi.org\/10.1007\/s11906-009-0077-7","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11,29]]}}}